A5068870798- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Asthma and respiratory diseases
- Pharmaceutical studies and practices
Hospital Clínico Universitario Virgen de la Victoria
2020-2023
Victoria School of Management
2023
Universidad de Málaga
2020
There are no studies which directly compare efficacy in Psoriasis Area and Severity Index (PASI) response of secukinumab ixekizumab. The main aim this study was to the safety both drugs used treat moderate-to-severe psoriasis patients over 52 weeks. Secondary objectives were identify factors related prior biologic treatment influenced their analyze data obtained at 12 A retrospective observational carried out, a group first 59 treated with after its commercialization, compared another 29...
There is a lack of real practice studies comparing ustekinumab and ixekizumab effectiveness safety. The main aim this study was to compare the safety both drugs used treat moderate-to-severe psoriasis patients over 52 weeks. secondary objective identify which clinical variables could have an impact on its effectiveness. A retrospective observational carried out, first 28 treated with after commercialization compared 35 ixekizumab. Although higher level skin clearance achieved PASI 90 100...